Responsive to the Restriction Requirement, Applicants elect Group XXVII (Claims 9-15, SEQ ID NO: 5), drawn to a method of analyzing a nucleic acid sample for a polymorphism, for prosecution. Applicants reserve the right to file a continuing application or take such other appropriate action as deemed necessary to protect the non-elected inventions. Applicants do not hereby abandon or waive any rights in the non-elected inventions.

Please amend the application as follows:

In the Claims

Please cancel Claims 1-8.

Please amend Claims 9, 10, 12 and 14. Amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (pages i - ii).

9. (Amended) A method of analyzing a nucleic acid sample for a polymorphism associated with cardiovascular disease, comprising the steps of:
   (a) obtaining a nucleic acid sample from one or more individuals, and
   (b) determining the nucleotide occupying the polymorphic site of SEQ ID NO: 5.

10. (Amended) A method according to Claim 9, wherein a plurality of nucleic acid samples is obtained from a plurality of individuals, and the nucleotide occupying one or more polymorphic sites is determined in each of the individuals.

12. (Amended) A method for predicting the likelihood that an individual will have a cardiovascular disease, comprising the steps of:
   (a) obtaining a nucleic acid sample from an individual to be assessed; and
   (b) determining the nucleotide present at the polymorphic site of one or more nucleic acid molecules having a nucleotide sequence comprising SEQ ID NO: 5,

wherein the presence of a nucleotide associated with a lower likelihood of having a cardiovascular disease indicates that the individual has a lower likelihood of having a cardiovascular disease than if another nucleotide were present at the polymorphic site.

14. (Amended) A method for predicting the likelihood that an individual will have a cardiovascular disease, comprising the steps of:

(a) obtaining a nucleic acid sample from an individual to be assessed; and

(b) determining the nucleotide present at the polymorphic site of one or more nucleic acid molecules having a nucleotide sequence comprising SEQ ID NO: 5,

wherein the presence of a nucleotide associated with a greater likelihood of having a cardiovascular disease indicates that the individual has a greater likelihood of having a cardiovascular disease than if another nucleotide were present at the polymorphic site.

Please add new Claims 16-20.

16. (New) The method of Claim 9, wherein the cardiovascular disease is coronary heart disease.

17. (New) A method for predicting the likelihood that an individual will have coronary heart disease, comprising the steps of:

(a) obtaining a nucleic acid sample from an individual to be assessed; and

(b) determining the nucleotide present at the polymorphic site of one or more nucleic acid molecules having a nucleotide sequence comprising SEQ ID NO: 5,

wherein the presence of a nucleotide associated with a lower likelihood of having coronary heart disease indicates that the individual has a lower likelihood of having a cardiovascular disease than if another nucleotide were present at the polymorphic site.

18. (New) The method of Claim 17, wherein cytidine is the nucleotide associated with a lower likelihood of having coronary heart disease present at the polymorphic site of SEQ ID NO: 5.